Literature DB >> 33786289

Histiocytic sarcoma following combination chemotherapy for primary mediastinal germ cell tumor: a diagnostic dilemma.

Hiroshi Yaegashi1, Yuki Kato1, Takahiro Nohara1, Kouji Izumi1, Yoshifumi Kadono1, Tohru Miyagi2, Takao Nakashima3, Kaori Yoshimura4, Yasunori Sato4, Kenichi Harada4, Atsushi Mizokami1.   

Abstract

Histiocytic sarcoma is considered an extremely rare condition. We herein report on a case of histiocytic sarcoma following combination chemotherapy for a primary mediastinal germ cell tumor in a 26-year-old Asian man who visited the General Medicine Department of a hospital with complaints of cough and high fever. Chest computed tomography (CT) imaging revealed a tumor (diameter 10.5 cm) in the anterior mediastinum, with no signs of metastasis, and CT-guided biopsy of the mediastinal tumor revealed the presence of some necrotic cartilages. The patient's serum α-fetoprotein (AFP) level was determined to be high at 160.4 ng/mL and a primary mediastinal non-seminomatous germ cell tumor was suspected, so the patient was referred to the Department of Urology. Despite the presence of severe thrombocytopenia, the patient was treated using a combination of chemotherapy and intermittent transfusion, which was able to normalize his serum AFP level. However, resection of the mediastinal tumor was unsuccessful due to persistent thrombocytopenia and the patient was subsequently transferred to our hospital for further examination and treatment. Despite management by hematologists, the condition of the patient did not improve; although his AFP level remained normal, the tumor increased in size and then metastasized to the liver and spleen. The general condition of the patient deteriorated and he died 9 months after his first visit. The patient was diagnosed with histiocytic sarcoma following a pathological autopsy. Due to the extremely rare incidence of histiocytic sarcoma, this condition should be a differential diagnosis and the appropriate tests must be conducted to give an exact treatment. © The Japan Society of Clinical Oncology 2021.

Entities:  

Keywords:  Cisplatin-based chemotherapy; Histiocytic sarcoma; Non-seminomatous germ cell tumor; Primary mediastinal germ cell tumor; Thrombocytopenia

Year:  2021        PMID: 33786289      PMCID: PMC7947123          DOI: 10.1007/s13691-020-00467-7

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  12 in total

1.  Mediastinal germ cell tumor associated with histiocytic sarcoma of spleen: case report of an unusual association.

Authors:  Sang Yong Song; Young Hyeh Ko; Geunghwan Ahn
Journal:  Int J Surg Pathol       Date:  2005-07       Impact factor: 1.271

2.  Mediastinal mixed germ cell tumor with splenic histiocytosis: A rare coincidence.

Authors:  Ridhi Sood; Anurag Mehta; Divya Bansal; Neha Singh; Sajjan Raj Purohit
Journal:  Indian J Pathol Microbiol       Date:  2019 Apr-Jun       Impact factor: 0.740

Review 3.  Histiocytic sarcoma : an updated literature review based on the 2008 WHO classification.

Authors:  Emiko Takahashi; Shigeo Nakamura
Journal:  J Clin Exp Hematop       Date:  2013

4.  Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib.

Authors:  Ahmed Idbaih; Karima Mokhtari; Jean-François Emile; Damien Galanaud; Hayat Belaid; Simon de Bernard; Neila Benameur; Vlad-Ciprian Barlog; Dimitri Psimaras; Jean Donadieu; Catherine Carpentier; Nadine Martin-Duverneuil; Julien Haroche; Loic Feuvret; Noel Zahr; Jean-Yves Delattre; Khê Hoang-Xuan
Journal:  Neurology       Date:  2014-09-10       Impact factor: 9.910

5.  BRAF(V600E) mutation in a histiocytic sarcoma arising from hairy cell leukemia.

Authors:  David Michonneau; Sophie Kaltenbach; Coralie Derrieux; Amelie Trinquand; Chantal Brouzes; Laure Gibault; Marie-Odile North; Richard Delarue; Bruno Varet; Jean-François Emile; Nicole Brousse; Olivier Hermine
Journal:  J Clin Oncol       Date:  2014-02-24       Impact factor: 44.544

6.  Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases.

Authors:  S A Pileri; T M Grogan; N L Harris; P Banks; E Campo; J K C Chan; R D Favera; G Delsol; C De Wolf-Peeters; B Falini; R D Gascoyne; P Gaulard; K C Gatter; P G Isaacson; E S Jaffe; P Kluin; D M Knowles; D Y Mason; S Mori; H-K Müller-Hermelink; M A Piris; E Ralfkiaer; H Stein; I-J Su; R A Warnke; L M Weiss
Journal:  Histopathology       Date:  2002-07       Impact factor: 5.087

7.  Malignant histiocytoses/disseminated histiocytic sarcoma with hemophagocytic syndrome in a patient with mediastinal germ cell tumor.

Authors:  Hiroko Shinoda; Akihiko Yoshida; Julie Teruya-Feldstein
Journal:  Appl Immunohistochem Mol Morphol       Date:  2009-07

8.  A case of histiocytic sarcoma presenting with primary bone marrow involvement.

Authors:  Byeong Seok Sohn; Tark Kim; Jeong Eun Kim; Eunsin Bae; Chan-Jeoung Park; Jooryung Huh; Sang-Oh Lee
Journal:  J Korean Med Sci       Date:  2010-01-19       Impact factor: 2.153

9.  Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms.

Authors:  Heounjeong Go; Yoon Kyung Jeon; Jooryung Huh; Suk Jin Choi; Yoo-Duk Choi; Hee Jeong Cha; Hyun-Jung Kim; Gyeongsin Park; Sookee Min; Ji Eun Kim
Journal:  Histopathology       Date:  2014-05-12       Impact factor: 5.087

10.  Mediastinal Germ Cell Tumor-associated Histiocytic Proliferations Treated With Thalidomide Plus Chemotherapy Followed by Alemtuzumab-containing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation: A Case Report.

Authors:  Li-Hua Fang; Li-Sun Shih; Pei-Ing Lee; Wei-Ting Chen; Rong-Long Chen
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

View more
  1 in total

1.  Survival Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Retrospective Single-institutional Experience.

Authors:  Hiroshi Yaegashi; Takahiro Nohara; Kazuyoshi Shigehara; Kouji Izumi; Yoshifumi Kadono; Tomoyuki Makino; Kaname Yamashita; Koushiro Ohtsubo; Hiroko Ikeda; Atsushi Mizokami
Journal:  Cancer Diagn Progn       Date:  2022-05-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.